Trial Profile
A Phase 2, Multi-Center, Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Iniparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 17 Mar 2023 Results from NCT01033292 and NCT01033123, published in the Oncologist
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2012 Planned number of patients changed from 48 to 43